Compare TG Therapeutics Inc (TGTX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TORM plc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while TORM plc trades at $29.05 (market cap $2.93B). The key difference: TG Therapeutics Inc is far larger — about 2.6× TORM plc's market cap, and TORM plc pays a 9.77% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TRMD | |
|---|---|---|
Market Cap | $7.64B | $2.93B |
Sector | Health | Technology |
52-Week High | $59.06 | $34.87 |
52-Week Low | $26.94 | $18.77 |
Enterprise Value | $7.84B | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
TRMD trades at $28.97, down 0.75% today, with technical indicators showing bearish momentum despite oversold RSI conditions. The company maintains strong fundamentals with a P/E of 8.4, net margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, supported by strong tanker market conditions and a $0.70 dividend declaration.
The stock presents a compelling value opportunity with attractive valuation metrics and 100% analyst buy ratings. Key risks include earnings volatility from freight rate fluctuations and negative net cash flow trends. Upside catalysts include potential merger discussions with Hafnia and sustained strong tanker market fundamentals through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
